The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction

Cardiovascular Therapeutics

Volumn 36, Issue 4, 2018, Pages

  Martens, Pieter ^a,b   Beliën, Hanne ^a   Dupont, Matthias ^a   Vandervoort, Pieter ^a,b   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

echocardiography; heart failure; left ventricular ejection fraction; reverse remodeling; sacubitril valsartan

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; DIASTOLIC FILLING TIME; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; BELGIUM; CONVALESCENCE; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR;

AGED; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; BELGIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; STROKE VOLUME; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85049846087     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12435     Document Type: Article

References (27)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717
5. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310
6. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800-2806
7. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol. 1997;29:1060-1066
8. Gotzsche CO, Sogaard P, Ravkilde J, Thygesen K. Effects of captopril on left ventricular systolic and diastolic function after acute myocardial infarction. Am J Cardiol. 1992;70:156-160
9. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573-2581
10. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080
11. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol. 2005;21:344-348
12. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970-975
13. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004
14. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200
15. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233-270
16. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: an Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314
17. Martens P, Verbrugge FH, Nijst P, et al. Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J Card Fail. 2017;23:597-605
18. Nijst P, Martens P, Mullens W. Heart failure with Myocardial Recovery - the patient whose heart failure has improved: what Next? Prog Cardiovasc Dis. 2017;60:226-236
19. Chan AK, Sanderson JE, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591-596
20. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102:1342-1347
21. Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115-1124
22. Rademaker MT, Charles CJ, Cooper GJ, et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension. 2002;39:93-98
23. von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8:71-78
24. Iborra-Egea O, Galvez-Monton C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12
25. Norberg H, Bergdahl E, Lindmark K. Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail. 2018;5:337-343
26. Packer M. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. Eur J Heart Fail. 2016;18:1211-1219
27. Packer M, Armstrong WM, Rothstein JM, Emmett M. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735-736